Supplementary Material for: Successful Treatment of Necrobiosis Lipoidica With Abrocitinib: A Case Report

Introduction: Necrobiosis lipoidica (NL) is a rare granulomatous disease with no standardized treatment guidelines.
Case Presentation: We present a case of a patient who experienced ulcerative NL of the left leg for five years, during which traditional treatments proved ineffective. The patient was administered oral abrocitinib at a dosage of 100 mg per day. After two weeks of treatment, the patient's skin lesions ceased exuding and began to show improvement. By the ten-week mark, the patient's symptoms had significantly improved, with the ulcer healing and no new lesions appearing. No adverse events were reported during the four-month follow-up period.
Conclusion: Abrocitinib may represent a rapid and safe treatment option for patients with refractory localized NL.Further studies are warranted to confirm these findings and evaluate long-term efficacy.